Welcome to Markets Desk, your midday read on the stories moving markets and money.
French biotech Abivax is the hardest hit name in equities today, with shares cratering thirty-two percent after the company released updated trial data on its lead bowel disease drug. The results clearly disappointed investors who had been pricing in a cleaner readout, and the selloff is sharp enough to effectively erase the takeover premium that had been baked into the stock.
Shifting to consumer and emerging markets, Coca-Cola confirmed it is exploring a public listing in India in two thousand twenty-seven for Hindustan Coca-Cola Holdings, the parent of its largest Indian bottling operation. The company also plans to sell part of its stake in the process, signaling a classic capital recycling move as multinationals increasingly look to unlock value in high-growth markets through local listings.
And finally, a story that cuts to the heart of index integrity. Fortune reports that S&P Dow Jones Indices is weighing changes to its profitability requirements for S&P five hundred inclusion, rules that have governed the benchmark for decades. If rewritten, private giants like SpaceX and Anthropic could benefit, but critics argue it dilutes the standard that passive investors have long relied on.
That's the tape. Markets Desk, signing off the floor.
